MCID: UTR033
MIFTS: 47

Uterine Corpus Cancer

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Uterine Corpus Cancer

MalaCards integrated aliases for Uterine Corpus Cancer:

Name: Uterine Corpus Cancer 12 14 69
Malignant Uterine Corpus Neoplasm 69
Corpus Uteri Cancer 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9460
ICD10 33 C54 C54.9
ICD9CM 35 182
NCIt 47 C3556
UMLS 69 C0153574

Summaries for Uterine Corpus Cancer

Disease Ontology : 12 A uterine cancer that is located in the uterine corpus.

MalaCards based summary : Uterine Corpus Cancer, also known as malignant uterine corpus neoplasm, is related to uterine corpus endometrial carcinoma and uterine body mixed cancer. An important gene associated with Uterine Corpus Cancer is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Pathways in cancer and Immune response IL-23 signaling pathway. The drugs Peppermint and Hormones have been mentioned in the context of this disorder. Affiliated tissues include lymph node, uterus and testes, and related phenotypes are Increased cell death HMECs cells and cellular

Related Diseases for Uterine Corpus Cancer

Diseases related to Uterine Corpus Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 107)
id Related Disease Score Top Affiliating Genes
1 uterine corpus endometrial carcinoma 11.0
2 uterine body mixed cancer 11.0
3 uterine corpus sarcoma 11.0
4 uterine corpus serous adenocarcinoma 11.0
5 congenital disorder of glycosylation, type if 10.7 ERBB2 TP53
6 animal phobia 10.7 ERBB2 TP53
7 signet ring basal cell carcinoma 10.6 ERBB2 MYC
8 cystic kidney disease 10.6 ERBB2 TP53
9 orbital lymphoma 10.6 ERBB2 TP53
10 bagatelle cassidy syndrome 10.6 MYC TP53
11 blastema predominant kidney wilms' tumor 10.6 PGR TP53
12 central nervous system organ benign neoplasm 10.6 PGR TP53
13 lung adenoma 10.6 PGR TP53
14 group b strep disease in newborns 10.6 ERBB2 TP53
15 gastritis 10.6 ERBB2 PGR
16 glaucoma, hereditary 10.6 ERBB2 PGR
17 breast myoepithelial neoplasm 10.5 PGR TP53
18 leiomyoma cutis 10.5 PGR TP53
19 intestinal perforation 10.5 PGR TP53
20 prostatic acinar adenocarcinoma 10.5 PGR TP53
21 skin sarcoma 10.5 ERBB2 PGR
22 her2-receptor negative breast cancer 10.5 ERBB2 PGR
23 subglottis verrucous carcinoma 10.5 ERBB2 PGR
24 intraductal breast myoepitheliosis 10.5 PGR TP53
25 hip subluxation 10.5 ERBB2 TP53
26 duodenal ulcer 10.5 MYC TP53
27 ovarian mesodermal adenosarcoma 10.5 PGR TP53
28 gastric tubular adenocarcinoma 10.5 ERBB2 PGR
29 her2-receptor positive breast cancer 10.5 ERBB2 PGR
30 vulvar keratoacanthoma-like carcinoma 10.5 MYC TP53
31 gastroesophageal junction adenocarcinoma 10.5 ERBB2 PGR
32 kallmann syndrome 10.5 ERBB2 PGR
33 cutaneous lupus erythematosus 10.5 BRCA1 ERBB2
34 penis squamous cell carcinoma 10.5 ERBB2 PGR
35 central nervous system germ cell tumor 10.5 PGR TP53
36 extragonadal nonseminomatous germ cell tumor 10.4 PGR TP53
37 kidney clear cell sarcoma 10.4 ERBB2 PGR
38 dmd-related dilated cardiomyopathy 10.4 ERBB2 PGR
39 malignant thyroid stimulating hormone producing neoplasm of pituitary gland 10.4 ERBB2 PGR
40 klatskin's tumor 10.4 ERBB2 PGR
41 comedo carcinoma 10.4 ERBB2 PGR
42 villous adenocarcinoma 10.4 ERBB2 MYC TP53
43 melanotic medulloblastoma 10.4 MYC TP53
44 acute thyroiditis 10.4 KIAA1324 PGR
45 septicemic plague 10.4 ERBB2 MYC TP53
46 gallbladder cancer 10.4 ERBB2 MYC TP53
47 anal paget's disease 10.3 ERBB2 PGR
48 autoimmune disease of blood 10.3 BRCA1 PGR
49 selective immunoglobulin deficiency disease 10.3 BRCA1 PGR
50 gastric cancer, somatic 10.3 ERBB2 MYC TP53

Graphical network of the top 20 diseases related to Uterine Corpus Cancer:



Diseases related to Uterine Corpus Cancer

Symptoms & Phenotypes for Uterine Corpus Cancer

GenomeRNAi Phenotypes related to Uterine Corpus Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death HMECs cells GR00103-A-0 9.02 BRCA1 FBXW7 MYC PGR TP53

MGI Mouse Phenotypes related to Uterine Corpus Cancer:

44 (show all 16)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.19 BRCA1 ERBB2 FBXW7 GATM KIAA1324 MYC
2 homeostasis/metabolism MP:0005376 10.11 BRCA1 ERBB2 FBXW7 GATM KIAA1324 MYC
3 behavior/neurological MP:0005386 10.1 KIAA1324 BRCA1 ERBB2 GATM MYC PGR
4 growth/size/body region MP:0005378 10.1 PKP3 TP53 BRCA1 ERBB2 FBXW7 GATM
5 cardiovascular system MP:0005385 10.09 BRCA1 ERBB2 FBXW7 MYC PGR PIK3R2
6 endocrine/exocrine gland MP:0005379 10.05 BRCA1 ERBB2 FBXW7 GATM MYC PGR
7 immune system MP:0005387 10.03 BRCA1 FBXW7 GATM KIAA1324 MYC PGR
8 hematopoietic system MP:0005397 10.02 BRCA1 FBXW7 GATM KIAA1324 MYC PGR
9 integument MP:0010771 10.01 BRCA1 ERBB2 FBXW7 GATM MYC PGR
10 embryo MP:0005380 10 BRCA1 ERBB2 FBXW7 MYC PGR TP53
11 muscle MP:0005369 9.87 BRCA1 ERBB2 GATM MYC PGR PIK3R2
12 neoplasm MP:0002006 9.8 TP53 BRCA1 ERBB2 FBXW7 MYC PGR
13 limbs/digits/tail MP:0005371 9.77 BRCA1 ERBB2 MYC PGR TP53
14 normal MP:0002873 9.7 PGR PKP3 TP53 BRCA1 ERBB2 FBXW7
15 reproductive system MP:0005389 9.5 BRCA1 ERBB2 GATM KIAA1324 MYC PGR
16 skeleton MP:0005390 9.1 BRCA1 ERBB2 GATM MYC PGR TP53

Drugs & Therapeutics for Uterine Corpus Cancer

Drugs for Uterine Corpus Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 329)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Peppermint Approved, Nutraceutical Phase 4
2 Hormones Phase 4,Phase 3,Phase 2,Phase 1
3 taxane Phase 4,Phase 1
4
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
5
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
6
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
7
Medroxyprogesterone acetate Approved, Investigational Phase 3,Phase 2 71-58-9
8
Levonorgestrel Approved, Investigational Phase 3,Phase 2 797-63-7, 17489-40-6 13109
9
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
10
Megestrol acetate Approved, Vet_approved Phase 2, Phase 3, Phase 1 595-33-5 11683
11
Progesterone Approved, Vet_approved Phase 3,Phase 2,Phase 1 57-83-0 5994
12
Menthol Approved Phase 3 2216-51-5 16666
13
Epirubicin Approved Phase 3 56420-45-2 41867
14
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
15
Tamoxifen Approved Phase 3,Phase 2,Phase 1 10540-29-1 2733526
16
Ifosfamide Approved Phase 3 3778-73-2 3690
17
Mechlorethamine Approved Phase 3 51-75-2 4033
18
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
19
Dactinomycin Approved Phase 3 50-76-0 2019 457193
20
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
21
Metformin Approved Phase 2, Phase 3, Phase 1, Early Phase 1 657-24-9 14219 4091
22
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
23
Aspirin Approved, Vet_approved Phase 3,Phase 2 50-78-2 2244
24
Bazedoxifene Approved, Investigational Phase 3 198481-32-2
25
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
26
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
27
Pyridoxal Approved, Nutraceutical Phase 3 66-72-8 1050
28
Pyridoxine Approved, Nutraceutical, Vet_approved Phase 3 65-23-6 1054
29
Dehydroepiandrosterone Approved, Nutraceutical Phase 3 53-43-0 9860744
30
Genistein Investigational Phase 3,Phase 1 446-72-0 5280961
31
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
32
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
33
Methylene blue Investigational Phase 3 61-73-4
34 Antithrombin III Phase 3
35 Antithrombins Phase 3
36 Fibrin fragment D Phase 3
37 Phytoestrogens Phase 3,Phase 2,Phase 1
38 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
39 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
40 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
41 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
42 Antimitotic Agents Phase 3,Phase 2,Phase 1
43 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
44 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1
45 Contraceptive Agents Phase 3,Phase 2,Phase 1
46 Contraceptive Agents, Male Phase 3,Phase 2
47 Contraceptives, Oral Phase 3,Phase 2,Phase 1
48 Estrogen Antagonists Phase 3,Phase 2,Phase 1
49 Estrogens Phase 3,Phase 2,Phase 1
50 Hormone Antagonists Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 601)

id Name Status NCT ID Phase Drugs
1 Upper Vaginectomy Versus Brachytherapy in Patients With Early Stage Endometrial Cancer Treated With Laparoscopic Surgery Unknown status NCT00719017 Phase 4
2 Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies Unknown status NCT01835119 Phase 4 gum
3 A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment Completed NCT00190697 Phase 4 arzoxifene
4 Biomarker Guided Treatment in Gynaecological Cancer Recruiting NCT02543710 Phase 4 Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer
5 Effects of the Concentrated Extract of Soy on Coagulation Factors After Menopause Unknown status NCT00925639 Phase 3 Isoflavone;Placebo
6 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
7 Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial Cancer Completed NCT00003749 Phase 3
8 Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer Completed NCT00006027 Phase 3 cisplatin;paclitaxel
9 Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer Completed NCT01767155 Phase 3 AEZS-108 / zoptarelin doxorubicin;doxorubicin
10 Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery Completed NCT00002807 Phase 3
11 Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer Completed NCT00005583 Phase 3 cisplatin;doxorubicin hydrochloride;epirubicin hydrochloride
12 External-Beam Radiation Therapy Compared With Vaginal Brachytherapy After Surgery for Stage I Endometrial Cancer Completed NCT00376844 Phase 3
13 Combination Chemotherapy With or Without G-CSF in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Completed NCT00003691 Phase 3 cisplatin;doxorubicin hydrochloride;paclitaxel
14 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer Completed NCT00002493 Phase 3 cisplatin;doxorubicin hydrochloride
15 Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus Completed NCT00002706 Phase 3
16 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
17 Tachosil for the Prevention of Symptomatic Lymph Cysts Completed NCT01470677 Phase 3 Tachosil fibrin patch
18 S9630, Medroxyprogesterone in Treating Women With Breast Cancer Completed NCT00002920 Phase 3 medroxyprogesterone;tamoxifen citrate
19 Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the Uterus Completed NCT00002459 Phase 3
20 Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer Completed NCT00245050 Phase 3 Placebo;doxorubicin HCL liposome
21 Resectoscopic Treatment of Atypical Endometrial Polyps in Fertile Women Completed NCT00490087 Phase 3
22 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
23 Pelvic Drains After Radical Hysterectomy in Treating Patients With Uterine, Cervical, or Vaginal Cancer Completed NCT00003267 Phase 3
24 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
25 Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis Completed NCT00033605 Phase 3 octreotide acetate
26 An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation Completed NCT00132704 Phase 3
27 Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women Completed NCT00003906 Phase 3 Raloxifene;Tamoxifen
28 Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis Completed NCT00670319 Phase 3 Raloxifene HCL;Raloxifene HCL;Placebo
29 Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia Completed NCT00003702 Phase 3 Methotrexate
30 Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer Recruiting NCT01244789 Phase 3 carboplatin and paclitaxel
31 Role of Uterine Manipulator in Hysterectomy - Ro.Man.HY Recruiting NCT02762214 Phase 3
32 Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
33 Megestrol Acetate Plus LNG-IUS in Young Women With Early Endometrial Cancer Recruiting NCT03241914 Phase 2, Phase 3 Megestrol Acetate
34 Indocyanine Green Versus Blue Dye for Detection of Sentinel Lymph Node In Endometrial Cancer Recruiting NCT02564276 Phase 3
35 Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol Recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
36 Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer Active, not recruiting NCT00063999 Phase 3 Carboplatin;Cisplatin;Doxorubicin Hydrochloride;Paclitaxel
37 An Endometrial Cancer Chemoprevention Study of Metformin Active, not recruiting NCT01697566 Phase 3 Metformin
38 Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer Active, not recruiting NCT00411138 Phase 3 cisplatin;carboplatin;Paclitaxel
39 Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
40 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Active, not recruiting NCT00807768 Phase 3 Carboplatin;Paclitaxel
41 Laparoscopic Approach to Cancer of the Endometrium Active, not recruiting NCT00096408 Phase 3
42 Oral Micronized Progesterone for Perimenopausal Vasomotor Symptoms Active, not recruiting NCT01464697 Phase 3 Oral micronized progesterone;placebo
43 Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia Active, not recruiting NCT01357772 Phase 3 Tamoxifen;placebo
44 Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer Active, not recruiting NCT01672892 Phase 3
45 Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms Active, not recruiting NCT01376349 Phase 3 prasterone
46 Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Active, not recruiting NCT01533207 Phase 3 Docetaxel;Doxorubicin Hydrochloride;Gemcitabine Hydrochloride
47 Finding the Best Dose of Aspirin to Prevent Lynch Syndrome Cancers Not yet recruiting NCT02497820 Phase 3 Aspirin
48 Intrauterine Levonorgestrel and Observation or Observation Alone in Preventing Atypical Endometrial Hyperplasia and Endometrial Cancer in Women With Hereditary Non-Polyposis Colorectal Cancer or Lynch Syndrome Terminated NCT00566644 Phase 3
49 Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent, Stage III, or Stage IV Endometrial Cancer Terminated NCT00016341 Phase 3 cisplatin;doxorubicin hydrochloride;megestrol acetate;paclitaxel;tamoxifen citrate
50 A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer Terminated NCT00883116 Phase 3 Ixabepilone;Doxorubicin;Paclitaxel

Search NIH Clinical Center for Uterine Corpus Cancer

Genetic Tests for Uterine Corpus Cancer

Anatomical Context for Uterine Corpus Cancer

MalaCards organs/tissues related to Uterine Corpus Cancer:

39
Lymph Node, Uterus, Testes, Cervix, Bone, Lung, Colon

Publications for Uterine Corpus Cancer

Articles related to Uterine Corpus Cancer:

(show all 29)
id Title Authors Year
1
Incidence and lifetime risk of uterine corpus cancer in Taiwanese women from 1991 to 2010. ( 28254229 )
2017
2
Reply to "Need for an up to date and comprehensive risk factor analysis to determine the lifetime risk of uterine corpus cancer in Taiwan women". ( 28805626 )
2017
3
Laparoscopic Repair of Vaginal Evisceration after Abdominal Hysterectomy for Uterine Corpus Cancer: A Case Report and Literature Review. ( 28502966 )
2017
4
Need for an up to date and comprehensive risk factor analysis to determine the lifetime risk of uterine corpus cancer in Taiwan women. ( 28805629 )
2017
5
Practice guidelines for management of uterine corpus cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement. ( 27894165 )
2017
6
A prediction model of survival for patients with bone metastasis from uterine corpus cancer. ( 27655906 )
2016
7
Lymphovascular space invasion in uterine corpus cancer: What is its prognostic significance in the absence of lymph node metastases? ( 27261326 )
2016
8
Genitofemoral neuropathy after pelvic lymphadenectomy in patients with uterine corpus cancer. ( 25486104 )
2015
9
Comorbidity is an independent prognostic factor in women with uterine corpus cancer: a nationwide cohort study. ( 24443826 )
2014
10
State-level uterine corpus cancer incidence rates corrected for hysterectomy prevalence, 2004 to 2008. ( 23125334 )
2013
11
Efficacy of para-aortic lymphadenectomy in early-stage endometrioid uterine corpus cancer. ( 21136177 )
2011
12
Comparative Performance of the 2009 International Federation of Gynecology and Obstetrics' Staging System for Uterine Corpus Cancer. ( 21705925 )
2011
13
Comparative performance of the 2009 International Federation of Gynecology and Obstetrics' staging system for uterine corpus cancer. ( 21508766 )
2011
14
Current status in the management of uterine corpus cancer in Korea. ( 20922137 )
2010
15
Comparative performance of the 2009 international Federation of gynecology and obstetrics' staging system for uterine corpus cancer. ( 20966700 )
2010
16
Comparison of second cancer risks from brachytherapy and external beam therapy after uterine corpus cancer. ( 20142245 )
2010
17
Evaluation of FDG-PET for detecting lymph node metastasis in uterine corpus cancer. ( 20944170 )
2010
18
Positron emission tomography with the glucose analog [F]-fluoro-2-deoxy-D-glucose for evaluating pelvic lymph node metastasis in uterine corpus cancer: comparison with CT and MRI findings. ( 19215544 )
2009
19
Comparison of the validity of magnetic resonance imaging and positron emission tomography/computed tomography in the preoperative evaluation of patients with uterine corpus cancer. ( 18201753 )
2008
20
Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer. ( 18064567 )
2008
21
FDG PET for the assessment of myometrial infiltration in clinical stage I uterine corpus cancer. ( 16710101 )
2006
22
The use of adjuvant radiation therapy in patients with intermediate-risk Stages IC and II uterine corpus cancer: a patient care evaluation study from the American College of Surgeons National Cancer Data Base. ( 16198401 )
2005
23
Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. ( 15581961 )
2004
24
Ethnic differences in uterine corpus cancer incidence and mortality in New Mexico's American Indians, hispanics and non-Hispanic whites. ( 9169158 )
1997
25
Identification of TP53 gene mutations in uterine corpus cancer with short follow-up. ( 9441778 )
1997
26
Correlation of C-myc and HER-2/neu amplification and expression with histopathologic variables in uterine corpus cancer. ( 7977518 )
1994
27
Estriol binding in uterine corpus cancer and in normal uterine tissues. ( 1869022 )
1991
28
Height and weight in relation to uterine corpus cancer morbidity and mortality. A follow-up study of 570,000 women in Norway. ( 2384266 )
1990
29
A cohort analysis of breast cancer, uterine corpus cancer, and childbearing pattern in Norwegian women. ( 2273359 )
1990

Variations for Uterine Corpus Cancer

Copy number variations for Uterine Corpus Cancer from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 162862 22 22706138 22714284 Decreasing copy numb er GSTT1 Corpus uteri cancer

Expression for Uterine Corpus Cancer

Search GEO for disease gene expression data for Uterine Corpus Cancer.

Pathways for Uterine Corpus Cancer

Pathways related to Uterine Corpus Cancer according to GeneCards Suite gene sharing:

(show all 39)
id Super pathways Score Top Affiliating Genes
1 12.51 ERBB2 MYC PIK3R2 TP53
2
Show member pathways
12.43 ERBB2 MYC PIK3R2 TP53
3
Show member pathways
12.37 ERBB2 MYC PIK3R2 TP53
4
Show member pathways
12.29 BRCA1 ERBB2 MYC PGR PIK3R2 TP53
5
Show member pathways
12.22 BRCA1 MYC TP53
6 12.2 BRCA1 ERBB2 MYC PIK3R2 TP53
7
Show member pathways
12.16 ERBB2 MYC PIK3R2 TP53
8 12.15 MYC PIK3R2 TP53
9 12.13 ERBB2 MYC PIK3R2 TP53
10
Show member pathways
12.09 ERBB2 MYC PIK3R2 TP53
11 12.04 MYC PIK3R2 TP53
12
Show member pathways
12.02 BRCA1 FBXW7 MYC PGR
13
Show member pathways
12 MYC PIK3R2 TP53
14
Show member pathways
11.99 ERBB2 MYC PIK3R2
15 11.93 MYC PIK3R2 TP53
16 11.92 BRCA1 MYC PIK3R2 TP53
17
Show member pathways
11.89 ERBB2 PIK3R2 TP53
18 11.85 MYC PIK3R2 TP53
19 11.82 MYC PIK3R2 TP53
20 11.77 ERBB2 MYC PIK3R2 TP53
21 11.68 MYC PIK3R2 TP53
22 11.52 BRCA1 ERBB2 MYC
23
Show member pathways
11.48 ERBB2 MYC PIK3R2
24 11.42 BRCA1 MYC TP53
25 11.42 ERBB2 MYC PIK3R2 TP53
26 11.35 BRCA1 MYC TP53
27 11.32 BRCA1 ERBB2 PIK3R2 TP53
28 11.31 BRCA1 MYC TP53
29 11.22 MYC PIK3R2
30 11.19 MYC TP53
31 11.17 BRCA1 TP53
32 11.16 BRCA1 TP53
33 11.12 BRCA1 TP53
34 11.1 MYC TP53
35 11.07 ERBB2 MYC PIK3R2 TP53
36
Show member pathways
10.99 MYC TP53
37 10.91 BRCA1 TP53
38 10.89 MYC PIK3R2 TP53
39 10.84 BRCA1 ERBB2 FBXW7 MYC TP53

GO Terms for Uterine Corpus Cancer

Biological processes related to Uterine Corpus Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.65 BRCA1 MYC PGR PIK3R2 TP53
2 response to gamma radiation GO:0010332 9.43 MYC TP53
3 negative regulation of fibroblast proliferation GO:0048147 9.4 MYC TP53
4 phosphatidylinositol 3-kinase signaling GO:0014065 9.37 ERBB2 PIK3R2
5 positive regulation of cell cycle arrest GO:0071158 9.32 BRCA1 TP53
6 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.16 BRCA1 TP53
7 phosphatidylinositol-mediated signaling GO:0048015 9.13 ERBB2 PIK3R2 TP53
8 positive regulation of gene expression GO:0010628 9.02 BRCA1 ERBB2 MYC PKP3 TP53

Molecular functions related to Uterine Corpus Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.26 BRCA1 PGR PKP3 TP53
2 protein phosphatase binding GO:0019903 8.8 ERBB2 PIK3R2 TP53

Sources for Uterine Corpus Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....